Overview of Sol-Gel Technologies Financial Results
Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company dedicated to developing innovative treatments for patients suffering from rare skin conditions, has recently provided insight into its financial performance for the third quarter of 2025. In this quarter, the company has made some strides and set ambitious goals for its pipeline of products and clinical trials.
Significant Developments in Q3 2025
One notable highlight includes Sol-Gel's decision to pursue high-frequency basal cell carcinoma (BCC) as a new treatment indication for its lead drug candidate, SGT-610. If approved, this strategic move could greatly enhance the commercial viability of the drug, effectively doubling its market potential. Additionally, Sol-Gel received Health Canada approval for EPSOLAY, which is poised to become a vital treatment option for inflammatory lesions of rosacea in adults.
Partnerships and Collaborations
Another significant corporate advance was the agreement signed with Viatris covering Australia and New Zealand for both EPSOLAY and TWYNEO. This collaboration aligns with Sol-Gel's broader strategy to capitalize on ex-U.S. markets, expanding its reach with strong partners in regions including Europe and Latin America.
Clinical Trial Progress
Sol-Gel is currently engaged in a Phase 3 clinical trial for SGT-610, targeted at Gorlin syndrome, with expectations for top-line results to be available in the fourth quarter of 2026. The growing interest from physicians in utilizing SGT-610 for severe high-frequency BCC underscores the potential impact of this drug in addressing significantly unmet medical needs. This includes compassionate use cases demonstrating the drug's promise among patients with specific genetic mutations.
Research and Development Efforts
The company is also exploring a feasibility study to assess SGT-610's application for high-frequency BCC, aiming to initiate a Phase 3 trial contingent upon the successful results from ongoing studies. The clinical landscape for treating high-frequency BCC is evolving, and Sol-Gel’s proactive approach highlights its commitment to tackling rare skin conditions.
Looking at Financials
In terms of financial performance, Sol-Gel reported total revenue of $0.4 million this quarter, reflecting a significant drop compared to the $5.4 million recorded in Q3 of 2024. This revenue mainly stemmed from licensing agreements outside the U.S. R&D expenditures saw an uptick, totaling $5.7 million, largely due to increased manufacturing and clinical trial costs for the SGT-610 candidate. Meanwhile, general and administrative expenses decreased to $1 million, indicating some cost-saving measures in place.
Financial Outlook and Challenges
With a net loss recorded at $5.9 million for the quarter, the company continues to navigate a challenging path, though it maintains $20.9 million in cash, cash equivalents, and marketable securities, which it anticipates will sustain operations into early 2027. The strategy to unlock value from product launches, particularly EPSOLAY and TWYNEO, positions the company for potential future growth as it strives toward its EBITDA target of $10 million by 2031.
Company Commitment to Innovation
Mr. Mori Arkin, Executive Chairman, stressed the company's commitment to advancing their pipeline and its goal to become a leader in treating dermatological rare diseases. The focus on innovative therapies not only benefits patients but is also central to creating value for shareholders.
About Sol-Gel Technologies
Sol-Gel Technologies is at the forefront of dermatology, focusing on developing and commercializing drug products tailored to treat skin diseases. With FDA-approved products like TWYNEO and EPSOLAY, the company is firmly established and continues to explore additional innovative solutions to meet patient needs.
Frequently Asked Questions
What recent financial results did Sol-Gel report?
For Q3 2025, Sol-Gel reported total revenue of $0.4 million, a decline from $5.4 million in the previous year.
What is SGT-610, and what potential does it have?
SGT-610 is a topical formulation intended for treatment in Gorlin syndrome, with potential applications for high-frequency basal cell carcinoma that could double its market potential.
What partnerships has Sol-Gel recently established?
Sol-Gel has signed agreements with Viatris to market EPSOLAY and TWYNEO in Australia and New Zealand, among other ongoing collaborations.
What are the anticipated timelines for future developments?
Top-line results for the Phase 3 study of SGT-610 are expected in the fourth quarter of 2026, with potential launches of products in new territories forecasted for 2028 and 2027, respectively.
How does Sol-Gel aim to sustain its operations?
The company holds about $20.9 million in cash and marketable securities, which is expected to fund its operations into early 2027.
